Category Archives: News

CapMan Buyout to sell Maintpartner’s operations in Finland, Estonia and Poland to Caverion

The funds managed by CapMan Buyout have agreed to sell Maintpartner Group Oy to Caverion.

Maintpartner is one of the leading industrial operation and maintenance companies in Northern Europe operating in Finland, Sweden, Estonia and Poland. Maintpartner provides services in the industrial sectors of energy, chemicals, metal, food and manufacturing. Maintpartner’s net sales were EUR 164 million in 2018, and the net sales of the entity now to be sold were EUR 137 million, most of which came from Finland.

”During CapMan’s ownership period Maintpartner has grown significantly and has established a firm foothold in various industrial sectors. In addition, the company has developed IoT solutions and machine learning analytics for industrial companies to improve their operation and maintenance processes. Maintpartner’s sale to Caverion Industrial Solutions Division provides an excellent basis for further growth and development of the operations”, comments Jan Mattlin, partner at CapMan Buyout.

The acquisition is in line with our Fit for Growth strategy and strengthens our Services business. Our Industrial Solutions division is now fit for growth and we are therefore entering the Growth phase in the division. The acquisition will focus our industrial operations more towards Services business and create a major player in the Finnish market,” says Ari Lehtoranta, CEO and President of Caverion Corporation.

The transaction is subject to approval by the competition authorities. The acquisition includes Maintpartner Group, while excluding the holding company Maintpartner Holding Oy and Maintpartner Group’s subsidiaries and operations in Sweden. The funds managed by CapMan Buyout and the other owners continue as the owners of Maintpartner Holding Oy. The funds managed by CapMan Buyout made an investment in Maintpartner in 2006.

CapMan Buyout is the largest mid-market private equity team in the Nordic region, with 12 investment professionals in Finland and Sweden and 30 years of experience.

For more information, please contact:

Jan Mattlin, partner, CapMan Buyout, tel. +358 40 508 6406

Martti Ala-Härkönen, CFO, Caverion Corporation, tel. +358 040 737 6633

Sakari Toikkanen, Head of Division Industrial Solutions, Caverion Industrial Solutions, tel. +358 040 532 2174

CapMan is a leading Nordic private asset expert with an active approach to value creation. We offer a wide selection of investment products and services. As one of the Nordic private equity pioneers, we have developed hundreds of companies and real estate assets and created substantial value in these businesses and assets over the past 30 years. CapMan employs today approximately 120 private equity professionals and has over €3 billion in assets under management. Our objective is to provide attractive returns and innovative solutions to investors. We have a broad presence in the unlisted market through our local and specialised teams. Our investment strategies cover Private Equity, Real Estate and Infra. We also have a growing service business that includes procurement services, fundraising advisory and fund management services. Altogether, CapMan employs 120 people in Helsinki, Stockholm, Copenhagen, London, Moscow and Luxembourg.

Categories: News

Tags:

CSAM Announces Deal to Acquire Arcid AS

Priveq

The transaction further strengthens CSAM’s leadership in the Nordic niche eHealth market
OSLO, Norway (March 12th, 2018) – CSAM announced today that it has signed an agreement
to acquire Arcid – a Norwegian eHealth company that focuses on information flow in the
teleradiology domain.

Arcid provides eHealth solutions that improve workflows and simplify the interaction between
healthcare professionals. Among the company’s best-known products are TRIS, a Radiology
Information System; Arcidis, a teleradiology information solution; and HelseMail, a Software as
Service (SaaS) communication platform that enables the encrypted transfer of large, high
volume, and sensitive patient information.

– The combination of CSAM and Arcid will create an innovative and comprehensive offering in
the medical imaging and connected health markets, enabling us to better serve clinicians and
patients, said Sverre Flatby, CSAM CEO. – Arcid has an impressive reputation for delivering
efficiency, quality, and exceptional patient care with their niche software solutions, and we are
pleased they have entrusted CSAM to carry on that tradition of excellence.

– I am confident that CSAM is the right home for Arcid’s team in this exciting growth period to
come, said Kåre-Bjørn Kongsnes, business developer and majority shareholder of Arcid. –
Integrating our highly competent team of people with CSAM, the leading Nordic niche player
within eHealth, strengthens this viable and powerful position.
The acquisition of Arcid is consistent with CSAM’s strategy to pursue growth through a
combination of strategic M&As and organic sales. The transaction is estimated to close before
the end of the month.

– Arcid’s products are an important complement to CSAM’s software solutions in the medical
imaging and connected healthcare domains, strengthening our leadership in these key market
segments, said Flatby. – The mixture of our customers, code and competencies will allow us to
provide even greater value to customers across both public and private healthcare
organisations.

CSAM has been a leading provider of medical imaging and connected healthcare solutions in
the Nordics for more than a decade. The company works closely with healthcare professionals
and organisations to develop software solutions that deliver the highest value for their
operations.

About CSAM
CSAM has established itself as a leading Nordic niche player in the specialised eHealth market
with a unique blend of best-in-class innovative technology, and outstanding human skills. The
company’s diverse portfolio of software solutions enables healthcare providers to access
relevant clinical information at the point of care. CSAM’s commercial headquarters are located
in Oslo, Norway. In addition to the new offices in Tromsø, the company also has local offices in
Stockholm, Karlstad, Gothenburg, Helsinki, Oulu, Tampere, and Warwickshire, as well as a
wholly owned software engineering subsidiary in the Philippines.

A privately-owned company backed by strong financial partners, CSAM aspires to achieve
continued growth both organically and through selected mergers and acquisitions. For more
information, visit www.csamhealth.com.

For more information, please contact:
Sverre Flatby, CEO Jennifer Goode, Communications Director
sverre.flatby@csamhealth.com jennifer.goode@csamhealth.com
+47 9159 9159 +1-705-760-0782
Kåre-Bjørn Kongsnes, Business Developer
kb@kongsnes.no
+47 900 11 040

Categories: News

Tags:

CXA Group Raises US$25 Million to Accelerate Expansion Across Asia-Pacific

Heritas

New investors HSBC, Singtel Innov8, Telkom Indonesia MDI Ventures, Sumitomo Corporation Equity Asia, Muang Thai Fuchsia Ventures, Humanica, Heritas Venture Fund and others join CXA’s latest financing round

This strategic capital will accelerate CXA’s growth momentum in the Asia-Pacific region and reinforce the company’s mission of improving the health and wellness of individuals through its employer-driven population health platform

CXA Group, Asia’s one-stop, predictive and data intelligence platform for better health, wealth and wellness choices, announced today that it has raised US$25 million in its latest round of funding. CXA’s new group of strategic investors include HSBC, Singtel Innov8, Telkom Indonesia MDI Ventures, Sumitomo Corporation Equity Asia, Muang Thai Fuchsia Ventures, Humanica and Heritas Venture Fund, underscoring the company’s aim to be the leading health ecosystem platform addressing escalating healthcare costs across the region.

The investment by these leading global financial services institutions, telecommunications providers and payroll companies reflect their belief in CXA’s long-term growth opportunity, and the company’s unique ability to shift healthcare spend from treatment to prevention, without employers spending more.

Rosaline Chow Koo, Founder and Chief Executive Officer, CXA Group said: “We are honoured to welcome these top-tier corporations into our roster of strategic investors and partners. CXA is today the leading health ecosystem platform that enables individuals across Asia to make better choices for healthier living, starting from the workplace, thereby empowering a shift in spend from treatment to prevention. We have seen overwhelming interest from global strategic investors who are excited to work with us to advance our business and vision.”

“These latest investors will become strategic partners, and we will look to closely collaborate in designing customised platform-led solutions for their B2B enterprise customers, and as importantly, the employees of these enterprises,” said Koo.

With chronic diseases hitting people in Asia earlier than in the West and healthcare costs escalating1, the company found that the antiquated pen-and-paper, one-size-fits-all approach to managing these costs was systemically wrong. This situation, if left unaddressed, would only get worse and become economically unsustainable over time.

The company has pioneered a one-stop, self-service platform that allows employers to give their employees access to an ever-widening range of health, wealth and wellness offerings, personalised based on the individual’s health and life-stage data. Employees can purchase offerings by drawing down on existing insurance policies provided by their employers and using funds that are then released into the platform’s eWallet to make transactions cashless, fast and easy.

Through the aggregation, anonymisation and analysis of digitised health and life-stage data, CXA helps employers get to the root cause of their workforces’ health issues and design specific interventions – such as corporate wellness and disease management initiatives – that will have the greatest impact on cost and health improvement, for reductions in tomorrow’s chronic disease and healthcare spend, today.

Headquartered in Singapore, CXA achieved revenue growth of 65 percent in 2018 and is expected to double that in 2019. This latest funding round follows US$33 million in total funding from Series A and B in 2015 and 2017 respectively. Other investors in CXA include B Capital Group, Openspace Ventures, Government-linked strategic investor EDBI, BioVeda Capital, FengHe Asia, Philips and RGAx.

Supporting Quotes from New Investors:

Edgar Hardless, Chief Executive Officer of Singtel Innov8 said, “CXA’s innovative use of analytics helps its enterprise clients effectively manage their healthcare costs and promote their employees’ wellbeing. We are excited to be an investor in CXA and help with their expansion across Asia.”

“CXA is rapidly emerging as a leader in the Health and Insurtech space. It has an innovative platform-led approach to helping companies optimise their health spend through personalised engagement with employees about their physical and financial wellness. We are excited about this investment partnership and the disruptive opportunities it presents,” said Bryce Johns, Group Head of Insurance, HSBC.

“Heritas invests in high-growth companies that are tackling major healthcare challenges faced by Asian populations,” said Chik Wai Chiew, Executive Director and CEO, Heritas Capital Management. “We are pleased to support CXA in this financing round to scale its employer-driven population health platform, as the company continues to pioneer solutions that connect the whole healthcare continuum and shift employers’ healthcare spend from treatment to prevention.”

Supporting Quotes from Previous Investors:

“Strategic investment in CXA from HSBC, Singtel Innov8 and others reinforces our belief in technology enablement and value creation from high-growth companies partnering with larger organisations and transforming in collaborative fashion. With the collective support of banks, insurers, telcos and payroll companies as co-investors, CXA can now accelerate its expansion into new markets and bancassurance channels, while creating new revenue opportunities for these partners’ businesses,” said Eduardo Saverin, Co-Founder and Partner, B Capital Group, the lead investor in CXA’s previous Series B funding round.

About CXA Group:

CXA Group is Asia’s one-stop, predictive and data intelligence platform for better health, wealth and wellness choices. Through the CXA platform, employers can empower employees with access to personalised health and lifestyle offerings, with clear and quantifiable ROI for the business. Founded in 2013 with the mission of transforming the delivery of employee benefits from pen-and-paper and one-size-fits-all to a digitised and personalised platform, the company aims to shift healthcare spend from treatment to prevention, to improve workplace population health.

Driven by a team of industry veterans with extensive leadership experience across Asia’s human resource, insurance, finance, healthcare and technology industries, CXA serves more than 600 enterprises, including Fortune 500 companies, and more than 400,000 employees in 20 countries. CXA has received recognition as InsurTech of the Year from the Asia Insurance Industry Awards and was among the top three most impactful innovations at the Singapore Digital Techblazer Awards.

Categories: News

Tags:

CSAM Announces Deal to Acquire Arcid AS

Priveq

The transaction further strengthens CSAM’s leadership in the Nordic niche eHealth market
OSLO, Norway (March 12th, 2018) – CSAM announced today that it has signed an agreement
to acquire Arcid – a Norwegian eHealth company that focuses on information flow in the
teleradiology domain.

Arcid provides eHealth solutions that improve workflows and simplify the interaction between
healthcare professionals. Among the company’s best-known products are TRIS, a Radiology
Information System; Arcidis, a teleradiology information solution; and HelseMail, a Software as
Service (SaaS) communication platform that enables the encrypted transfer of large, high
volume, and sensitive patient information.

– The combination of CSAM and Arcid will create an innovative and comprehensive offering in
the medical imaging and connected health markets, enabling us to better serve clinicians and
patients, said Sverre Flatby, CSAM CEO. – Arcid has an impressive reputation for delivering
efficiency, quality, and exceptional patient care with their niche software solutions, and we are
pleased they have entrusted CSAM to carry on that tradition of excellence.

– I am confident that CSAM is the right home for Arcid’s team in this exciting growth period to
come, said Kåre-Bjørn Kongsnes, business developer and majority shareholder of Arcid. –
Integrating our highly competent team of people with CSAM, the leading Nordic niche player
within eHealth, strengthens this viable and powerful position.
The acquisition of Arcid is consistent with CSAM’s strategy to pursue growth through a
combination of strategic M&As and organic sales. The transaction is estimated to close before
the end of the month.

– Arcid’s products are an important complement to CSAM’s software solutions in the medical
imaging and connected healthcare domains, strengthening our leadership in these key market
segments, said Flatby. – The mixture of our customers, code and competencies will allow us to
provide even greater value to customers across both public and private healthcare
organisations.

CSAM has been a leading provider of medical imaging and connected healthcare solutions in
the Nordics for more than a decade. The company works closely with healthcare professionals
and organisations to develop software solutions that deliver the highest value for their
operations.

About CSAM
CSAM has established itself as a leading Nordic niche player in the specialised eHealth market
with a unique blend of best-in-class innovative technology, and outstanding human skills. The
company’s diverse portfolio of software solutions enables healthcare providers to access
relevant clinical information at the point of care. CSAM’s commercial headquarters are located
in Oslo, Norway. In addition to the new offices in Tromsø, the company also has local offices in
Stockholm, Karlstad, Gothenburg, Helsinki, Oulu, Tampere, and Warwickshire, as well as a
wholly owned software engineering subsidiary in the Philippines.
A privately-owned company backed by strong financial partners, CSAM aspires to achieve
continued growth both organically and through selected mergers and acquisitions. For more
information, visit www.csamhealth.com.

For more information, please contact:
Sverre Flatby, CEO Jennifer Goode, Communications Director
sverre.flatby@csamhealth.com jennifer.goode@csamhealth.com
+47 9159 9159 +1-705-760-0782
Kåre-Bjørn Kongsnes, Business Developer
kb@kongsnes.no
+47 900 11 040

Categories: News

Tags:

Partners Group to invest in delivery of 500MW subsea interconnector between Great Britain and Ireland

Partners Group

Partners Group, the global private markets investment manager, has provided equity financing for the Greenlink Interconnector (“Greenlink”), a project to construct a 500MW subsea interconnector between Ireland and Great Britain, on behalf of its clients. To-date, Greenlink has been developed by Element Power, an independent renewable energy developer, which, together with funds managed by Hudson Sustainable Investments, is the other major shareholder in Greenlink.

Greenlink will use a subsea high-voltage direct current (HVDC) cable system to connect the power markets of Ireland and Great Britain, improving the security of electricity supply in both countries and reducing average electricity costs for consumers. It will stretch approximately 200km underground and under the sea between County Wexford in Ireland and Pembrokeshire in Wales. The project is considered of critical importance in Europe and has been awarded “Project of Common Interest” status by the European Commission as well as granted funding from the EU’s Innovation and Networks Executive Agency. Construction is scheduled to commence in 2020 and is expected to be completed by 2023.

Esther Peiner, Managing Director, Private Infrastructure Europe, Partners Group, states: “Greenlink Interconnector is a key electricity infrastructure project for Ireland and Great Britain. With the build-out of renewable energy generation in both countries, particularly the growth of offshore wind, infrastructure like Greenlink is essential to facilitate the low carbon economy as it will allow surplus renewable power to be exported between the two countries. Once completed, this interconnector will not only benefit consumers in Great Britain and Ireland, but will also enhance security of supply.”

Categories: News

Tags:

KKR and Tivoli Capital to Develop New Co-Working Locations in France

KKR

France, 12 March 2019: KKR, a leading global investment firm, and Tivoli Capital, a specialist in real estate development in France and the creator of the iLOV’iT Worklabs co-working space, have signed an agreement for the development of a new generation of office buildings in France’s largest cities.

The co-working market in France is developing rapidly. The concept, launched in the United States over 15 years ago and now fully developed in London, Amsterdam, Frankfurt and Madrid, grew by 80% between 2016 and 2017 in France, according to JLL’s 2018 global market report. Entrepreneurialism is growing in France, driven by increases in project-based work, working remotely and the importance of work-life balance.

The new developments build on the success of iLOV’iT, the largest co-working center in Marseille, with a surface area of almost 3,700m2, private offices, shared spaces and meeting rooms with well-being services. Tivoli Capital aims to develop its platform in this market, following the agreement with KKR. The new generation of offices will focus on having a welcoming working environment and offering various services adapted to the needs of residents. It will offer an alternative solution to entrepreneurs who want flexible, ready-to-use offices without long-term commitment.

Guillaume Pellegrin, Founder of Tivoli Capital, said “From the beginning, we wanted to develop our presence in France. We are pleased to have signed an agreement with KKR, who will support us in all areas of our development. Our goal is to transform the market, putting human beings at the heart of our project to be able to offer the ideal workspace in the 2020s for entrepreneurs and companies, regardless of their size, in all major French cities.”

Mai-Lan de Marcilly, Director at KKR in the European Real Estate team, said “Guillaume and his team have real expertise in the acquisition and development of innovative real estate projects within France, with a unique approach to improving quality of life at work. With this agreement, our aim is to become a leader in the French professional co-working space.”

KKR’s investment was made through its Real Estate Partners Europe fund.

About KKR

KKR is a leading global investment firm that manages multiple alternative asset classes, including private equity, energy, infrastructure, real estate and credit, with strategic partners that manage hedge funds. KKR aims to generate attractive investment returns for its fund investors by following a patient and disciplined investment approach, employing world-class people, and driving growth and value creation with KKR portfolio companies. KKR invests its own capital alongside the capital it manages for fund investors and provides financing solutions and investment opportunities through its capital markets business. References to KKR’s investments may include the activities of its sponsored funds. For additional information about KKR & Co. Inc. (NYSE:KKR), please visit KKR’s website at www.kkr.com and on Twitter @KKR_Co.

About Tivoli Capital

Created by Guillaume Pellegrin in Marseille, TIVOLI CAPITAL offers a wide range of real estate and financial services for investors wishing to diversify into regional markets. With a recognized know-how, the company has valued more than 250,000 m2 since its origin, and managed nearly 500 million euros of real estate assets for the Caisse des Dépôts, CEPAC, Carlyle, COVIVIO, and Primonial. Tivoli also managed the property and the financial director of The Camp, the first European campus dedicated to emerging technologies and the city of tomorrow. More information on www.tivoli-capital.com.

Media contacts for KKR:

France
Adding Value Conseils
Olivier Blain: ob@addingvalueconseils.com / + 33 6 72 28 29 20
Florence Taieb: ft@addingvalueconseils.com / +33 6 71 90 40 57

UK & International
Alastair Elwen, Finsbury
Email: alastair.elwen@finsbury.com
Phone: +44(0)20 7251 3801

Media contacts for Tivoli Capital:
Eve Leporq
Tel: +33 6 62 46 84 82
Email: eve@votredircom.fr

Categories: News

Tags:

CSAM Announces Deal to Acquire Arcid AS

Priveq

The transaction further strengthens CSAM’s leadership in the Nordic niche eHealth market

OSLO, Norway (March 12th, 2018) –CSAM announced today that it has signed an agreement to acquire Arcid –a Norwegian eHealth company that focuses on information flow in the tele radiology domain.

Arcid provides eHealth solutions that improve workflows and simplify the interaction between healthcare professionals. Among the company’s best-known products are TRIS, a Radiology Information System;Arcidis, a teleradiology information solution;and HelseMail, a Software as Service (SaaS) communication platform that enables theencrypted transferof large, high volume, and sensitive patient information.

-The combination of CSAM and Arcid will create an innovative and comprehensive offering in the medical imaging and connected health markets, enabling us to better serve clinicians and patients, said Sverre Flatby, CSAM CEO. –Arcid has an impressive reputation for delivering efficiency, quality, and exceptional patient care with their niche software solutions, and we are pleased they have entrusted CSAM to carry on that tradition of excellence.

-I am confident that CSAM is the right home for Arcid’s team in this exciting growth period to come, said Kåre-Bjørn Kongsnes, business developer and majority shareholder of Arcid. –Integrating our highly competent team of people with CSAM, the leading Nordic niche player within eHealth, strengthens this viable and powerful position.

The acquisition of Arcid is consistent with CSAM’s strategy to pursue growth through a combination of strategic M&As and organic sales. The transaction is estimated to close before the end of the month.

-Arcid’s products are an important complement to CSAM’s software solutions in the medical imaging and connected healthcare domains, strengthening our leadership in these key market segments, said Flatby. -The mixture of our customers, code and competencies will allow us to provide even greater value to customers across both public and private healthcare organisations.

CSAM has been a leading provider of medical imaging and connected healthcare solutions in the Nordics for more than a decade.The company works closely with healthcare professionals and organisations to develop software solutions that deliver the highest value for their operations.

About CSAM

CSAM has established itself as a leading Nordic niche player in the specialised eHealth marketwith a unique blend of best-in-class innovative technology, and outstanding human skills. The company’s diverse portfolio of software solutions enables healthcare providers to access relevant clinical information at the point of care. CSAM’scommercialheadquarters are located in Oslo, Norway. In addition to the new offices in Tromsø, the companyalso has local offices in Stockholm, Karlstad, Gothenburg, Helsinki, Oulu, Tampere, and Warwickshire, as well as a wholly owned software engineering subsidiary in the Philippines.

A privately-owned company backed by strong financial partners, CSAM aspires to achieve continued growth both organically and through selected mergers and acquisitions. For more information, visit www.csamhealth.com.

For more information, please contact:

Sverre Flatby, CEOJennifer Goode, Communications Directorsverre.flatby@csamhealth.comjennifer.goode@csamhealth.com+47 9159 9159+1-705-760-0782Kåre-Bjørn Kongsnes, Business Developerkb@kongsnes.no+47 900 11 040

Categories: News

Tags:

Gilde Healthcare acquires healthcare food supplier Eetgemak from Value8

GIlde Healthcare

Gilde Healthcare’s investment allows Eetgemak to realize new growth plans, including expansion into Belgium

Utrecht and Frankfurt – Gilde Healthcare, the European specialist investor in healthcare, acquires a majority stake in Eetgemak from stock listed investment firm Value8. The acquisition is the first investment in Gilde Healthcare’s new €200 million private equity fund focused on the healthcare industry. Katwijk based Eetgemak is the market leader in chilled meals for Dutch healthcare institutions. With Gilde as a new investor, Eetgemak will further expand its market position by growing in both existing as well as new markets, like Belgium.

Doctors and dietitians increasingly recognize the importance of tasty, healthy food that meets the patient’s wishes in the healing process. At the same time, there is a constant pressure on healthcare institutions to work more efficiently and to provide better care with less staff. With an assortment of thousands of different chilled meals, Eetgemak offers hospitals, care institutions and people at home healthy meals at low prices. Moreover, through its scale and expertise, Eetgemak is able to cater to the many types of dietary needs of patients and residents in care institutions.

The investment in Eetgemak fits well in Gilde Healthcare’s new private equity fund: “We look for companies that contribute to the improvement of care. Moreover, we actively contribute to the development of our portfolio companies through our specific knowledge and experience in the healthcare industry. We are very excited about Eetgemak’s growth opportunities and look forward to a productive collaboration,” says Hugo de Bruin, partner at Gilde Healthcare.

“Gilde’s investment enables us to execute our growth strategy, not only in the Netherlands, but also across the border in Belgium. In addition to accelerating organic growth, we are also interested in new partnerships and potential acquisitions,” says Leo van der Krogt, CEO at Eetgemak.

About Eetgemak

Eetgemak prepares chilled meals for hospitals, home care organizations, care centers, nursing homes, expertise centers, service apartments, living communities, restaurants, caterers, schools and daycare centers. Professional chefs prepare a wide range of seasonal dishes with great pleasure every day. Our motto is ‘everyone joins for dinner’. Whether it’s preference, meal type, consistency or diet; taste and quality are always paramount. Everyone deserves a healthy, fresh and tasty meal. This is why every day we cook fresh and healthy meals with the best ingredients. https://www.eetgemak.nl

About Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing €1 billion across two fund strategies: private equity and venture & growth capital. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies including healthcare providers, suppliers of medical products and service providers, with a primary focus on the Benelux and DACH regions. Gilde Healthcare’s venture & growth fund is focused on fast growing health tech and therapeutics companies based in Europe and North America. https://gildehealthcare.com

 

Media Contacts

Gilde Healthcare

Hugo de Bruin
Partner
Newtonlaan 91
3584BP Utrecht
The Netherlands
debruin@gildehealthcare.com
+31 (0)30 219 2565

Eetgemak

Leo van der Krogt
CEO
Taanderstraat 9a
2222 BG Katwijk
The Netherlands
leo@eetgemak.nl
+31 (0)71 408 4140

Categories: News

Tags:

New brand launches next generation payment solutions

ik-investment-partners

The well-known Nordic brands OpenSolution (Sw), KDR (No) and Finnpos (Fi) have joined forces under the new brand OPEN. “We wanted a brand that reflects our value proposition – delivering innovative and customized payment solutions, helping our customers to plan, perform and grow their businesses,” says CEO Mikael Hedlöf.

OPEN covers the entire value chain of payment solutions, making it a single point of contact for >13,000 customers throughout the Nordics and Baltics with 18,000 systems installed. In conjunction with the rebranding, OPEN will also launch the next generation of Point of Sale (POS) solutions to restaurants, convenience stores and the cruise ship segment.

“We know that an innovative payment solution can increase a company’s revenue by up to 30% as well as improve employee wellbeing in the workplace. With this in mind, we reinvented our POS experience to better suit the fast-paced business environment. We are proud to say that OPEN’s system is the market’s most complete cash register system with everything from hardware, payment solutions, reporting tools, integrations and support,” commented Mikael Hedlöf, CEO of OPEN.

Restaurant chain ‘The Barn’ is one of the clients who has tested OPEN’s new POS system.

“Having tested OPEN’s new POS offering, we are thoroughly impressed by its functionality and innovative features.  Our collaboration with OPEN helps us grow as a company,” said Marcus Martinsson, CEO at The Barn.

For more information, please contact:
Mikael Hedlöf, CEO
mikael.hedlof@openpos.tech
+46 (0)70-283 76 28

Categories: News

Tags:

Gilde Healthcare leads EUR 20M Series A financing round of Calypso Biotech

GIlde Healthcare

Utrecht, The Netherlands and Boston, US – Calypso Biotech (Amsterdam, The Netherlands), an emerging leader in the development of therapeutic antibodies for autoimmune diseases, announces today the closing of a €20M Series A financing led by Gilde Healthcare and Inkef Capital. They are joined by Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and the company’s founding investor M Ventures. Further, Calypso Biotech has become Resident Company at Johnson & Johnson Innovation JLABS at Beerse in Belgium (JLABS@BE). Arthur Franken from Gilde Healthcare will join the Board of Directors.

The proceeds from this financing round will support the development of Calypso Biotech’s best-in class anti-Interleukin-15 (IL-15) antibody CALY-002 up to First-in-Patient studies in several autoimmune indications. IL-15 is an immune checkpoint cytokine that controls inflammation as well as multiple tissue-resident immune cells and recently attracted much attention in the immune-oncology space. Especially, IL-15 is being recognized as a key factor in the survival of tissue resident memory T cells, a population of immune cells involved in disease maintenance and recurrence. Calypso Biotech scientists believe that targeting tissue resident memory T cells offers significant advantages over traditional cytokine interventional approaches and could provide for unprecedented disease-modifying effects.

Calypso Biotech has chosen to develop CALY-002 in Eosinophilic Esophagitis (EoE) as well as in other undisclosed auto-immune indications. EoE is a severe and debilitating immune-related chronic disease of the esophagus that is the second leading cause of dysphagia (difficulty in swallowing) in adults. EoE has emerged as a frequent and significant cause of upper gastrointestinal morbidity particularly associated with important quality of life impairment and significant financial healthcare burden. CALY-002 has secured Orphan Drug Designation status from the European Medicines and Food & Drug Administration agencies for EoE.

Calypso Biotech is also announcing major strengthening of its team. Bernard Coulie, current president and CEO of Pliant Therapeutics, will be appointed as independent Chairman of the Board. Together with Alexandre LeBeaut, Executive Vice-President and CSO of Ipsen and current independent Director of Calypso Biotech, they will contribute to develop its strategic vision and corporate success. Prof. Bart Lambrecht, from the VIB-UGent Center for Inflammation Research (Belgium), a leading translational immunology expert, will join Calypso Biotech Scientific Advisory Board. Dr. Josephin-Beate Holz (ex Ablynx NV), Dr Greg Elson (ex Glenmark, Novimmune), Dr Susana Salgado (ex Novimmune), and Duc Tran (ex Prexton Therepeutics, Preglem, Pfizer) will join as medical, manufacturing, non-clinical development and strategic planning advisors, respectively.

About Calypso Biotech BV
Calypso Biotech BV is a private biotechnology company focused on the research and
development of novel biologics to address unmet medical need in immunological diseases, especially gastrointestinal indications. Calypso Biotech was established in 2013 as a spin-off by the healthcare business of Merck founded by Alain Vicari, Yolande Chvatchko and M Ventures, and is headquartered in Amsterdam, The Netherlands. Calypso is led by a team with strong experience and track record in translational immunology and the development of biologics, supported by an advisory board of clinical experts. For more information www.calypsobiotech.com

About Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing €1 billion ($1.2 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market.
For more information www.gildehealthcare.com

Categories: News

Tags: